“In our balance sheet, if you exclude cash and if I have to analyze our performance in the first half, we are almost at 50% plus ROCEs. So it is a business where given the opportunity that exists, we will focus on ensuring that we continue to deliver market beating growth.”
Dr Reddy’s Labs Q4 Results: Cons PAT jumps 22% to Rs 1,594 crore; Rs 8 per share dividend announced
Dr Reddy’s Labs Q4 Results: Dr Reddy’s Laboratories on Friday reported a consolidated net profit growth of 22% to Rs 1,594 crore in Q4FY25 versus